The US FDA issues EUA for Johnson & Johnson’s single-dose COVID-19 vaccine

Pharmaceutical

The US Food and Drug Administration (FDA) has issued emergency use authorisation for Johnson & Johnson’s single-dose COVID-19 vaccine.

The authorisation swiftly followed a positive meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee, which unanimously backed a EUA for the jab.

“The US FDA issues EUA for Johnson & Johnson’s single-dose COVID-19 vaccine. “

Briefing documents that were published endorsed the efficacy and safety of the vaccine and reiterated its effectiveness of sixty-six-point-one per cent in a Phase III trial.

J&J stated that it’s expecting to distribute one-hundred million single-dose vaccines to the US during the first six months of 2021.

Chief scientific officer, J&J, Paul Stoffels, stated: “We believe the Johnson & Johnson single-shot COVID-19 vaccine is a critical tool for fighting this global pandemic, particularly as it shows protection across countries with different variants. A vaccine that protects against COVID-19, especially against the most dire outcomes of hospitalisation and death, will help ease the burden on people and the strain on health systems worldwide."

See all the latest jobs in Pharmaceutical
Return to news